We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
Turnover
18.46%
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
(+43%)
Cap. Flow
+$26.4M
Cap. Flow
% of AUM
14.57%
Top 10 Holdings %
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.5
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$7.2M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$4.5M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$2.46M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.28M |
| 5 |
Merck
MRK
|
+$2.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$5.34M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$1.78M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$1.76M |
| 4 |
Pacira BioSciences
PCRX
|
+$1.59M |
| 5 |
Esperion Therapeutics
ESPR
|
+$1.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.5% |
| 2 | Miscellaneous | 40.37% |
| 3 | Financials | 0.14% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
ProShares Ultra NASDAQ Biotechnology
BIB
$93.3M
| $1.91M | 1.05% |
32,717
-20,851
| -39% | -$1.78M |
2014 Q4
3 quarters
|
|
27
DELISTED
Hologic
HOLX
| $1.88M | 1.04% |
48,000
| – | – |
2014 Q4
3 quarters
|
|
|
NSTG
28
DELISTED
NanoString Technologies, Inc.
NSTG
| $1.64M | 0.9% |
102,200
+42,200
| +70% | +$661K |
2015 Q2
1 quarter
|
|
29
DELISTED
Array Biopharma Inc
ARRY
| $1.14M | 0.63% |
250,000
-70,000
| -22% | -$415K |
2014 Q4
3 quarters
|
|
|
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
| $926K | 0.51% |
56,788
+5,000
| +10% | +$110K |
2014 Q4
3 quarters
|
|
31
Vericel Corp
VCEL
$2.1B
| $900K | 0.5% |
332,157
-30,000
| -8% | -$98.5K |
2014 Q4
3 quarters
|
|
|
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
| $887K | 0.49% |
65,700
+28,200
| +75% | +$509K |
2015 Q1
2 quarters
|
|
|
33
Pacira BioSciences
PCRX
$1.45B
| $863K | 0.48% |
21,000
-26,000
| -55% | -$1.59M |
2015 Q1
2 quarters
|
|
34
Amgen
AMGN
$235B
| $778K | 0.43% |
5,626
+76
| +1% | +$12K |
2014 Q4
3 quarters
|
|
35
Curis
CRIS
$1.23M
| $756K | 0.42% |
187
+79
| +73% | +$447K |
2015 Q2
1 quarter
|
|
|
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
| $733K | 0.4% |
106,104
+39,400
| +59% | +$321K |
2014 Q4
3 quarters
|
|
37
United Therapeutics
UTHR
$23.2B
| $731K | 0.4% |
5,571
+172
| +3% | +$27.6K |
2014 Q4
3 quarters
|
|
38
CALL
Novavax
NVAX
$2.11B
| $707K | 0.39% |
+5,000
| New | +$1.12M |
2015 Q3
0 quarters
|
|
|
39
PUT
Novavax
NVAX
$2.11B
| $707K | 0.39% |
+5,000
| New | +$1.12M |
2015 Q3
0 quarters
|
|
|
STML
40
DELISTED
Stemline Therapeutics, Inc.
STML
| $662K | 0.37% |
75,000
| – | – |
2014 Q4
3 quarters
|
|
|
EPZM
41
DELISTED
Epizyme, Inc
EPZM
| $593K | 0.33% |
46,079
-26,300
| -36% | -$531K |
2014 Q4
3 quarters
|
|
42
DELISTED
Chimerix, Inc.
CMRX
| $541K | 0.3% |
14,152
-5,000
| -26% | -$247K |
2014 Q4
3 quarters
|
|
43
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $528K | 0.29% |
7,881
-1,271
| -14% | -$104K |
2014 Q4
3 quarters
|
|
44
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
| $494K | 0.27% |
+98,000
| New | +$749K |
2015 Q3
0 quarters
|
|
45
Gilead Sciences
GILD
$195B
| $424K | 0.23% |
4,323
+89
| +2% | +$9.88K |
2014 Q4
3 quarters
|
|
|
SIOX
46
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $397K | 0.22% |
+3,840
| New | +$450K |
2015 Q3
0 quarters
|
|
|
INFI
47
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $383K | 0.21% |
45,300
-34,700
| -43% | -$320K |
2015 Q2
1 quarter
|
|
48
Arrowhead Research
ARWR
$8.26B
| $295K | 0.16% |
51,133
-31,000
| -38% | -$195K |
2014 Q4
3 quarters
|
|
|
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $290K | 0.16% |
+7,150
| New | +$379K |
2015 Q3
0 quarters
|
|
|
NHLD
50
DELISTED
National Holdings Corporation
NHLD
| $246K | 0.14% |
89,530
| – | – |
2015 Q1
2 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q3 2015 Portfolio in Review
As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.
- Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
- Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
- Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
- Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
- Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
- Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
- Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.
Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.